You are here: Industry Insights > Janssen

News List

Provention Bio Announces Licensing Agreements with Janssen americanpharmaceuticacreview
September 22, 2017
Provention Bio has entered into agreements with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC [Janssen] to in-license two clinical-stage assets
Janssen reveals positive CHMP opinion, long-term data for psoriasis drug guselkumab pharmafile
September 20, 2017
Janssen has announced that its psoriasis drug guselkumab has been awarded a positive opinion by the EMA’s Committee for Medicinal Products for Human Use (CHMP)
Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight worldpharmanews
September 19, 2017
Johnson & Johnson (NYSE: JNJ) announced that Janssen is working with the US Department of Health and Human Services's Office of Preparedness and Response Assistant Secretary (ASPR)
Janssen to stop further development of JNJ-4178 hepatitis C treatment pharmaceufical-technology
September 14, 2017
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) and commonly affects the liver.
Janssen to Discontinue Hepatitis C Development Program prnasia
September 11, 2017
Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B
Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments pharmaceufical-technology
September 06, 2017
Vokanamet is approved in the European Union (EU) to improve glycaemic control in adult patients with type 2 diabetes.
FDA turns down Janssen's sirukumab for rheumatoid arthritis pharmafile
August 04, 2017
Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the rheumatoid arthritis (RA) space
Janssen receives EMA committee recommendation to market Symtuza for HIV pharmaceutical-technology
July 27, 2017
Janssen-Cilag International (Janssen) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Symtuza for the treatment of HIV.
Janssen single tablet regimen shows Phase 3 success in HIV pharmafile
July 27, 2017
The latest Phase 3 data investigating Janssen’s darunivir in the treatment of human immunodeficiency virus (HIV-1) showed that the drug was effective and safe, Janssen has announced.
Janssen Biotech’s Tremfya receives FDA approval for plaque psoriasis treatment pharmaceutical-technology
July 18, 2017
The US Food and Drug Administration (FDA) has granted approval for Janssen Biotech’s Tremfya (guselkumab) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page